跳至主要内容
临床试验/NCT01302002
NCT01302002撤回早期 1 期

The Use of Metformin in Early Breast Cancer Patients Pre-Surgery: A Phase 0 Study Regarding The Biological Effect

Instituto Nacional de Cancer, Brazil1 个研究点 分布在 1 个国家开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
撤回
发起方
试验地点
1
主要终点
To determine the in situ effects of metformin in women with operable stage I or II breast cancer

研究概览

简要总结

The study will test metformin in patients with early breast cancer. Blood and tissue will be collected before and after the use of metformin.

详细描述

Patients will take metformin twice a day for 3 weeks before surgery. The hypothesis is that metformin will reduce cell proliferation rates (Ki67) and increase apoptoses (TUNEL)in tumor tissue.

The study will collect and analyze pre- and post-treatment blood specimens for:

  • Serum glucose
  • Insulin levels
  • Estradiol
  • HOMA test
  • Glycosylated haemoglobin

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Invasive breast cancer T1 or T2, Nx
  • Knowledge of the investigational nature of the study and ability to provide consent for study participation

排除标准

  • Diabetes or baseline glucose or Glycosylated haemoglobin upper limit of normal for the institution
  • Recent use of corticosteroids
  • AST > 1.5 times upper limit of normal for the institution
  • Pregnancy
  • Serious clinical illness
  • Prior or concurrent systemic neoadjuvant Breast Cancer therapy.

研究组 & 干预措施

Metformin Pre-Surgery

Experimental

Patients will take metformin twice a day for three weeks prior surgery

干预措施: Metformin Pre-Surgery (Drug)

结局指标

主要结局

To determine the in situ effects of metformin in women with operable stage I or II breast cancer

时间窗: 60 days after the surgery

To determine the in situ effects of metformin on * proliferation (Ki67) and apoptosis (TUNEL), fosforilate AKT * CD1a CD83, CD68, F40/80, arginase iNOS and T cells -CD4(+),CD45RA(+), CD 45RO, CD4, CD8 and FOXP3(+).

次要结局

  • To analyse gastrointestinal toxicity(One week , 2 weeks and 20 days after Metformim beginning)
  • To analyse the blood tests one day before the biopsy and one day before the surgery(5 days after blood collection)

研究者

发起方
Instituto Nacional de Cancer, Brazil
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Ana Elisa Lohmann

Medical Oncologist

Instituto Nacional de Cancer, Brazil

研究点 (1)

Loading locations...

相似试验